Zoetis Inc. (NYSE:ZTS) EVP Roxanne Lagano Sells 326 Shares of Stock

Zoetis Inc. (NYSE:ZTS) EVP Roxanne Lagano sold 326 shares of the company’s stock in a transaction on Monday, March 10th. The stock was sold at an average price of $170.00, for a total transaction of $55,420.00. Following the transaction, the executive vice president now owns 15,781 shares of the company’s stock, valued at $2,682,770. This trade represents a 2.02 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Roxanne Lagano also recently made the following trade(s):

• On Tuesday, February 11th, Roxanne Lagano sold 326 shares of Zoetis stock. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68.

Zoetis Trading Down 4.3 %

NYSE:ZTS opened at $164.39 on Wednesday. The firm has a 50-day simple moving average of $166.94 and a 200-day simple moving average of $176.55. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. Zoetis Inc. has a one year low of $144.80 and a one year high of $200.33. The firm has a market cap of $73.61 billion, a P/E ratio of 30.05, a P/E/G ratio of 2.78 and a beta of 0.94.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, topping the consensus estimate of $1.37 by $0.03. The company had revenue of $2.32 billion for the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. Equities analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be paid a $0.50 dividend. This represents a $2.00 annualized dividend and a dividend yield of 1.22%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis’s dividend payout ratio is currently 36.56%.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Barclays upped their target price on shares of Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a report on Friday, February 14th. StockNews.com upgraded shares of Zoetis from a “hold” rating to a “buy” rating in a research note on Friday, March 7th. Piper Sandler raised their price target on shares of Zoetis from $200.00 to $205.00 and gave the company an “overweight” rating in a report on Thursday, February 27th. UBS Group assumed coverage on shares of Zoetis in a research report on Monday, December 9th. They set a “neutral” rating and a $196.00 price objective on the stock. Finally, Leerink Partners assumed coverage on shares of Zoetis in a research report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 target price on the stock. One equities research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $215.90.

Hedge Funds Weigh In On Zoetis

Several large investors have recently made changes to their positions in the company. Mission Wealth Management LP grew its holdings in shares of Zoetis by 2.0% during the fourth quarter. Mission Wealth Management LP now owns 2,938 shares of the company’s stock worth $479,000 after buying an additional 59 shares in the last quarter. Hancock Whitney Corp raised its holdings in Zoetis by 0.3% in the third quarter. Hancock Whitney Corp now owns 18,569 shares of the company’s stock valued at $3,628,000 after acquiring an additional 61 shares in the last quarter. Strategy Asset Managers LLC raised its holdings in Zoetis by 3.5% during the third quarter. Strategy Asset Managers LLC now owns 1,822 shares of the company’s stock worth $356,000 after purchasing an additional 62 shares in the last quarter. VeraBank N.A. raised its holdings in Zoetis by 4.1% during the fourth quarter. VeraBank N.A. now owns 1,562 shares of the company’s stock worth $254,000 after purchasing an additional 62 shares in the last quarter. Finally, HUB Investment Partners LLC grew its position in shares of Zoetis by 4.7% during the fourth quarter. HUB Investment Partners LLC now owns 1,373 shares of the company’s stock worth $224,000 after acquiring an additional 62 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.